← Eichor
Study identifier: NCT04966663 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Using ctDNA to Determine Therapies for Lung Cancer

Condition: Non Small Cell Lung Cancer · Complete Surgical Resection · Circulating Tumor DNA  ·  Sponsor: University Health Network, Toronto

PhasePhase 2
Planned participants66
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Natasha Leighl, M.D.  ·  416-946-4645  ·  Natasha.Leighl@uhn.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Princess Margaret Cancer CentreToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04966663